Skip to main content

PTGX Protagonist Therapeutics, Inc.

Healthcare

135.26 USD 1D -8.11 -5.66% Close 11/5
Since 2024-12-05 +244.0%

Close 11/5

Open
142.56
High
143.30
Low
134.39
Prev close
143.37
Volume
582.61K
Amplitude
6.21%
P/E
138.7
P/B
11.0
Revenue YoY (TTM)
+34.8%
52W 76.70 160.81
FinLab Studio

From Protagonist Therapeutics, Inc. to every stock like it

AI finds several complementary traits of Protagonist Therapeutics, Inc. across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like Protagonist Therapeutics, Inc.

Is Protagonist Therapeutics, Inc. a buy? Fundamentals and valuation first

As of 2026-11-04

Quality: Good, Growth: Good, Momentum: Good, Risk / liquidity: Good; Valuation: Pricey.

Valuation Pricey Free-cash-flow yield is Good, but TTM P/E is Expensive.
TTM P/E 138.7 95th percentile · Expensive
Price / book 11.0 93th percentile · Expensive
Free-cash-flow yield (%) 1.4 53th percentile · Good
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Good FCF margin, TTM is Top; ROE, TTM is Good.
ROE, TTM (%) 9.9 65th percentile · Good
Operating margin, TTM (%) 20.7 73th percentile · Good
FCF margin, TTM (%) 46.9 92th percentile · Top
Quality Factor Investing: A US Quality Value Backtest
Growth Good Revenue growth, TTM YoY is Top; Diluted EPS growth, TTM YoY is Good.
Revenue growth, TTM YoY (%) 34.8 83th percentile · Top
Diluted EPS growth, TTM YoY (%) 47.7 76th percentile · Good
Momentum Good 240-day return is Top; 60-day return is Good.
60-day return (%) -3.3 55th percentile · Good
240-day return (%) 68.4 91th percentile · Top
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Good 20-day dollar volume is Top; 60-day annualized volatility is Good.
20-day dollar volume 95,099,009.0 86th percentile · Top
60-day annualized volatility (%) 32.1 35th percentile · Good
Factor Investing Explained: 10 Classic Factors in US Stocks

Protagonist Therapeutics, Inc. (PTGX) today

2 quant signals active · As of 2026-11-04

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

Protagonist Therapeutics, Inc. (PTGX) peers and tracking

Watchlist

This page refreshes daily after the close. Add Protagonist Therapeutics, Inc. to your watchlist to track signal changes on your next visit.

Protagonist Therapeutics, Inc. (PTGX) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Top-quintile 6-month momentum

Active · now 86.4%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

Momentum Trading Strategy: A 12-1 Momentum Backtest
25 historical occurrences (since 2017-02-10)

Average forward return after Top-quintile 6-month momentum

20-day: Win 58.3%, Sample 24, Median +4.2%, Excess +0.5%, Beat mkt rate 50.0%

60-day: Win 58.3%, Sample 24, Median +11.1%, Excess +5.4%, Beat mkt rate 54.2%

120-day: Win 73.9%, Sample 23, Median +17.3%, Excess +14.3%, Beat mkt rate 60.9%

120 days after: historical avg +22.2%

20-day +2.0%
60-day +9.4%
120-day +22.2%
20-day
60-day
120-day
Win
58.3%
58.3%
73.9%
Sample
24
24
23
Median
+4.2%
+11.1%
+17.3%
Excess
+0.5%
+5.4%
+14.3%
Beat mkt rate
50.0%
54.2%
60.9%

Over 23 occurrences, 120-day forward avg gained 22.2%, beat the market by 14.3 pts; win rate 73.9%.

Filed revenue acceleration

Active · now 34.8%

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

8 historical occurrences (since 2020-08-06)

Average forward return after Filed revenue acceleration

20-day: Win 50.0%, Sample 8, Median +0.5%, Excess +3.0%, Beat mkt rate 50.0%

60-day: Win 87.5%, Sample 8, Median +11.8%, Excess +10.6%, Beat mkt rate 87.5%

120-day: Win 85.7%, Sample 7, Median +29.2%, Excess +23.0%, Beat mkt rate 71.4%

120 days after: historical avg +31.2%

20-day +4.6%
60-day +12.8%
120-day +31.2%
20-day
60-day
120-day
Win
50.0%
87.5%
85.7%
Sample
8
8
7
Median
+0.5%
+11.8%
+29.2%
Excess
+3.0%
+10.6%
+23.0%
Beat mkt rate
50.0%
87.5%
71.4%

Over 7 occurrences, 120-day forward avg gained 31.2%, beat the market by 23.0 pts; win rate 85.7%.

More history: Market-wide momentum baseline, Signals not active now

Market-wide momentum baseline

Across 100,217 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.37%, a 58.3% positive-return rate, and +3.03 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

23 times historically; 60-day forward avg +0.1%, win rate 52.2%, beating the market by -4.9 pts on average.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

PEAD: Post-Earnings Announcement Drift Backtest

17 times historically; 60-day forward avg +15.4%, win rate 70.6%, beating the market by +11.6 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.